RxDoctor Payments Data

Jeremy Wilt, NP

Family · Charlestown, INNPI 1043689672

Payments from drug & device makers

$10,672in general payments, 2019–2025

Across 212 payments — averaging $50.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$5K
  • Sumitomo Pharma America, Inc.$1K
  • Medtronic$581
  • Procept Biorobotics Corporation$511
  • Endo USA, Inc.$500
  • Verity Pharmaceuticals Inc.$386
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$380%
  • Travel & lodging$3,31031%
  • Food & beverage$7,25968%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,672 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$224,247
Medicare patients
1,262
Services billed
5,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron110$99,432
GemtesaVibegron35$39,564
XyostedTestosterone Enanthate12$7,414
Estradiol33$2,485
Fosfomycin Tromethamine22$2,437
Testosterone Cypionate69$2,408
Tamsulosin Hcl168$2,318
Cefdinir84$952
Dutasteride14$938
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst63$755
Finasteride48$744
Alfuzosin Hcl ErAlfuzosin Hcl40$655
Doxycycline Monohydrate50$546
Fluconazole44$318
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$228$99,432110 claims
Sumitomo Pharma America, Inc.Gemtesa$1,285$39,56435 claims
Antares Pharma, Inc.Xyosted$224$7,41412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Charlestown

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →